Sanofi Rheumatoid Arthritis Drug Cuts Pain, Damage in Study
This article is for subscribers only.
Sanofi and Regeneron Pharmaceuticals Inc.’s experimental rheumatoid arthritis drug eased symptoms and damage caused by the disease in a clinical trial, advancing its prospects to compete in a market led by Roche Holding AG.
In a study of 1,200 patients for whom the standard treatment methotrexate wasn’t sufficient, sarilumab plus methotrexate eased pain and stiffness twice as much as those who got methotrexate alone, and slowed joint destruction 90 percent more, the two companies said in a joint statement today.